Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

Launched by MỸ ĐỨC HOSPITAL · Jul 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a combination treatment using two medications, liraglutide and metformin, on weight loss and pregnancy rates in women who have polycystic ovary syndrome (PCOS), obesity, and infertility. PCOS is a common condition that can lead to issues with hormones, weight, and fertility. The goal of the study is to see if this combination can help improve health and increase the chances of becoming pregnant, especially for women who are planning to undergo fertility treatments like in vitro fertilization (IVF).

To be eligible for this trial, participants need to be women aged 18 to 65 who have been diagnosed with PCOS and have a body mass index (BMI) of 27 or higher, which indicates obesity. They should also be experiencing infertility and agree to participate in the study. However, women who have certain health conditions, such as diabetes or a history of specific cancers, or those taking certain medications that affect weight or hormones, are not eligible. Participants can expect to receive support and monitoring throughout the trial as they try this new treatment approach, which aims to improve their overall health and fertility outcomes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female gender
• • 18-65 years of age
• • Diagnosis of polycystic ovary syndrome according to the revised Rotterdam criteria (2003)
• • BMI ≥ 27 kg/m2
• • Infertility
• • Agree to participate in the study
• Exclusion Criteria:
• • Type 1 or type 2 diabetes.
• • History of acute or chronic pancreatitis.
• • Family or individual history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
• • Known hypersensitivity or contraindication to the use of GLP-1 receptor agonists.
• • Used of hormonal drugs, drugs causing clinically significant weight changes and drugs affecting glucose tolerance for at least 8 weeks.
• • Used a anti-androgen drugs for at least 4 weeks.
• • History of malignancy requiring chemotherapy.
• • History of taking antidiabetic drugs other than gestational diabetes or weight-loss drugs discontinued for at least 4 weeks.
• • History of gastrectomy or device-based intervention to manage obesity
• • Eating disorders (anorexia or bulimia) or digestive disorders.
• • Substance abuse (Tobacco or alcohol)
• • History of major depression or other serious mental disorder.
• • Inability or refusal to adhere treatment regimens.